Clinical trial · Interventional
Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy
Receiving Modified Chemotherapy Followed With Radical Resection After Neoadjuvant Chemotherapy Versus Receiving the Original Chemotherapy in Locally Advanced Gastric Cancer: a Randomized Controlled Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
For patients undergoing postoperative therapy for locally advanced gastric cancer after neoadjuvant chemotherapy, we assessed the utility of graded histologic regression of \<50% as the criterion of treatment change. Sixty patients will be enrolled to randomize into two groups：receiving modified chemotherapy and receiving the original chemotherapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Paclitaxel/DDP | Drug | — | UNRESOLVED |
| XELOX/SOX | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- receiving modified chemotherapy
- description
- Paclitaxel/DDP
- interventionNames
- Drug: Paclitaxel/DDP
- type
- ACTIVE_COMPARATOR
- label
- receiving the original chemotherapy
- description
- XELOX/SOX
- interventionNames
- Drug: XELOX/SOX
Primary outcomes (1)
- measure
- disease free survival
- timeFrame
- 3 year
- description
- DFS between two arms
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * TNM stage of T2-T4 or positive regional lymph nodes, according to the American Joint Committee on Cancer (AJCC) 7.0 staging system, verified by enhanced abdominal computed tomography (CT) and/or endoscopic ultrasound (EUS), positron emission tomography (PET)/CT scan), with no evidence of distant metastases; * ECOG performance status score ≤2 without serious heart, lung, liver, kidney, or hematological dysfunctions; * age ≥18 years old; * no previous chemotherapy, radiotherapy, or surgical treatment for gastric cancer; * gastrectomy was performed after preoperative chemotherapy if imaging studies did not confirm disease progression (according to the Response Evaluation Criteria in Solid Tumors (RECIST)) ; * signed the informed consent form. Exclusion Criteria: * All do not reach the inclusion criteria
References
Publications (0)
Data not yet available